Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study Mallada-Frechin, J Meca-Lallana, V Barrero Hernández, Francisco Javier Martínez-Ginés, ML Marzo-Sola, ME Ricart, J García, E 2024-09-04T07:59:49Z 2024-09-04T07:59:49Z 2018-09 journal article Mallada-Frechin J, Meca-Lallana V, Barrero F, Martinez-Gines ML, Marzo-Sola ME, Ricart J, Garcia E, En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN. Efectividad y seguridad del fingolimod en la practica clinica habitual en pacientes con esclerosis multiple remitente recurrente en España: analisis intermedio del estudio MS NEXT [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study]. Rev Neurol. 2018 Sep 1;67(5):157-167. Spanish. PMID: 30047118. 1576-6578 https://hdl.handle.net/10481/93893 spa http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Viguera